tag:blogger.com,1999:blog-7923005810906159036.post2732675743752254455..comments2024-03-27T12:49:05.975+00:00Comments on IP finance: Restasis royalty dispute finally settlesAnne Fairpohttp://www.blogger.com/profile/02579190868405783459noreply@blogger.comBlogger1125tag:blogger.com,1999:blog-7923005810906159036.post-91797245987286674862010-04-23T13:05:47.509+01:002010-04-23T13:05:47.509+01:00There are always "yes buts" for anyone u...There are always "yes buts" for anyone unfamiliar with the situation, however, retrospective analysis was not a factor in this case. Allergan and UGARF went to great lengths to hide their negotions from Kaswan correctly anticipating that she would object to the monetization. Allergan included a $1.5M enticement to UGARF for legal defense. Normative behavior would have allowed UGARF and Kaswan to evaluate their individual incentives for monetization. Most Universities give their inventors the option to participate in a monetization or retain their original license terms for their share of the new deal. Along with the rights conveyed to it by academic inventors, Universities have responsibilities to their inventors to be trusted custodians of their beneficiary interessts in their IP.Renee Kaswan DVM, DACVOhttps://www.blogger.com/profile/07018099635725955674noreply@blogger.com